The global cell line development market is estimated to reach US$8.719 billion by 2030 from US$5.359 billion in 2025, growing at a CAGR of 12.73%.
Cell line is defined as the population of cells that can be maintained in culture for a longer period. Cell line development is the technique through which the cellular machinery manufactures therapeutic proteins. This enables researchers in biomedical research to optimize and produce drugs at a cost-efficient scale. One of the major drivers for the global cell line development market growth is the expanding pharmaceutical and medicine sector in the world. The growth of global pharmaceutical and medicine products will enable manufacturers to develop more cost-effective drugs to advance in the commercial market.
The Eurostat stated that the region’s medicine and pharmaceutical products imports increased from about US$120 billion (Euro 112 billion) in 2022 to about US$128.7 billion (Euro 119 billion) in 2023. In this import, Belgium became the biggest importer of medicinal and pharmaceutical products in the region, importing about US$28.1 billion (Euro 26 billion), followed by Germany and the Netherlands at US$21.6 billion (Euro 20 billion) and US$17.3 billion (Euro 16 billion) respectively, in 2023.
Monoclonal antibodies are the type of antibodies that are engineered and produced in research laboratories to act as substitute antibodies, which can further mimic the immune system’s attack on cells. The cell line development process offers an efficient development and production of various biological products, like monoclonal antibodies and vaccines.
The rise in the global cases of deadly diseases, like cancer, COVID-19, Ebola, and others, is estimated to boost the growth of monoclonal antibodies, further increasing the global market share of cell line development. With the rise in cases of diseases worldwide, the global demand for vaccines has increased significantly. The World Integrated Trade Solution stated that in 2023, Belgium's total import of vaccines for human medicine accounted for US$12.433 billion, followed by the US at about US$9.274 billion and the EU at US$7.376 billion. The imports of China and Germany in 2023 accounted for about US$6.225 billion and US$4.665 billion, respectively.
The mammalian cell line development category, under the source segment of the global cell line development market, is expected to grow at a higher rate, during the forecasted timeline. Mammalian cell line development is the process through which growing cells are obtained from mammals in vitro. Mammalian cell line development allows biological therapies of genetic instructions, like CHO cells. Mammalian cells also help in the processing and secretion of eukaryotic proteins. Mammalian cell line also provides multiple benefits compared to bacterial cell culture.
Mammalian cell line development offers its application across multiple types of cell development, which include vaccine production, cell & gene therapies, drug discovery & development, recombinant protein production, and fundamental research among others. The major factor propelling the growth of the mammalian cell line development is the increasing demand for recombinant protein across the global market. Various global research institutes and cell line development sector companies announced the introduction of key solutions, that enable the mass production of recombinant proteins. For instance, in May 2024, the Indian Institute of Science, a key research institute in India, announced the launch of a Novel method, for the mass production of recombinant proteins.
Similarly, the introduction of enhanced cell line development solutions for mammalian cell line development is also expected to boost the growth of the market. In January 2024, Abzena, a global biotechnology leader, announced the launch of the CLD platform, AbZelect, which helps accelerate the manufacturing of antibodies and recombinant proteins, utilizing the cell line process. The increasing demand for drug discovery in the global pharmaceutical or biotechnology industry is also among the key factors propelling the growth of the mammalian cell line in the global cell line development market. During the drug discovery pipeline, the mammalian cell line is widely used along different phases, which include from discovery phase to the pre-clinical phase. Drug discovery is the research procedure of identifying and developing newer drug components, that can help in enhancing the efficacy of the drugs from multiple diseases. The demand for drug discovery witnessed a major growth with the increasing global cases of chronic diseases, which include cardiovascular diseases and cancer.
The cell line development market in the United States is experiencing significant growth, driven by technological advancements, increasing demand from various industries, and a strong focus on energy efficiency. Developed economies such as the United States are anticipated to account for significant growth during the projected period in the cell line development market. This is owing to the rising research and development initiatives coupled with increased investment in advanced processes in the country.
Additionally, the increasing investment in research regarding biosimilars by companies in the United States will drive demand for cell line large-scale production in the coming years. For instance, in 2024, US Food and Drug Administration (USFDA) gave approval to Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar for the treatment of two rare diseases. Similarly, the administration also authorizes various proteins on an annual basis including recombinant and therapeutic proteins as well. This highlights the rising need for vaccines, pharmaceuticals, biosimilars, and therapeutic proteins that will propel the growth of cell line development in the country.
Furthermore, the key developments in the market by major players are anticipated to boost long-term growth. For instance, in 2023, Berkeley Lights, Inc., one of the leading companies in the United States, announced the launch of Beacon Select, the new optofluidic system for cell line development (CLD). The product is a two-chip beacon system that enables scientists to culture, clone, and select the top clone in a single run using a single platform. This is ideally most suitable for small to mid-sized biopharma set-ups and other CROs/CDMOs as well. Moreover, CIRM (California Institute of Regenerative Medicine), in its 2024 April meeting, announced an investment of around US$89 million in various clinical programs. Such interventions are expected to provide impetus for the cell line development market, thereby also providing favorable ground for advancement in cell-based vaccines in the forecast period .
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Report Metric | Details |
| Cell Line Development Market Size in 2025 | US$5.359 billion |
| Cell Line Development Market Size in 2030 | US$8.719 billion |
| Growth Rate | CAGR of 12.73% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Forecast Unit (Value) | USD Billion |
| Segmentation |
|
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| List of Major Companies in the Cell Line Development Market |
|
| Customization Scope | Free report customization with purchase |